CytoMed Executive Chairman and substantial shareholder, Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake in CytoMed to 2.50% as of today. In addition, our Chairman is also a 55% shareholder of Glorious Finance Limited, and the sole shareholder of EP Capital Inc, representing 2,282,422 shares, or 19.45% of the Company. In aggregate, he owns 2,388,246 shares representing 21.95% of the Company’s total outstanding shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed Therapeutics Bids for TC BioPharm’s Assets Amid Strategic Expansion
- Cytomed announces cash bid for potential acquisition of TC BioPharm
- CytoMed Therapeutics Unveils Promising AML Therapy Research
- Cytomed Therapeutics announces publication of research on T cells
- CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges